Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.95 |
| ▸ | PGR | P06401 | 3/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | AR | P10275 | 2/20 | 0.95 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | APEX1 | P27695 | 1/20 | 0.95 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.95 |
| ▸ | IKBKB | O14920 | 1/20 | 0.95 |
| ▸ | CHUK | O15111 | 1/20 | 0.95 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.95 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.95 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.95 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL2637829 | 1.00 | HIF1A (0.95) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL1376472 | 1.00 | HIF1A (0.95) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL11911310 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13046610 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL12738245 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL24556970 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21790369 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21261932 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL20816248 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL23022353 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4792032-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| CN-101039668-A | Pharmaceutical formulations comprising an antibiotic, a triazole and a corticosteroid | SCHERING PLOUGH LTD (CH) | 2007-09-19 | — | — | CN | claimed |
| EP-1776109-A1 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTIBIOTIC, A TRIAZOLE AND A CORTICOSTEROID | Schering-Plough Ltd. (CH) | 2007-04-25 | — | — | EP | claimed |
| US-20060122159-A1 | Pharmaceutical formulation | INTERVET INC. | 2006-06-08 | — | — | US | claimed |
| WO-2006020689-A1 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTIBIOTIC, A TRIAZOLE AND A CORTICOSTEROID | SCHERING-PLOUGH LTD. (CH) | 2006-02-23 | — | — | WO | claimed |
| WO-2019010491-A1 | DRUG COMBINATIONS FOR PROTECTING AGAINST NEURONAL CELL DEATH | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-10 | — | — | WO | disclosed |
| US-9259442-B2 | Method and means for producing tissues and tissues obtained | PHILIPPART PIERRE (BE) | 2016-02-16 | — | — | US | disclosed |
| US-20150037394-A1 | DRUG DELIVERY FORMULATIONS | KING'S COLLEGE LONDON | 2015-02-05 | — | — | US | disclosed |
| EP-2723318-A2 | DRUG DELIVERY FORMULATIONS | King's College London (GB) | 2014-04-30 | — | — | EP | disclosed |
| WO-2012175996-A2 | DRUG DELIVERY FORMULATIONS | KING'S COLLEGE LONDON (GB) | 2012-12-27 | — | — | WO | disclosed |
| US-20120027740-A1 | METHOD AND MEANS FOR PRODUCING TISSUES AND TISSUES OBTAINED | PHILIPPART PIERRE (BE) | 2012-02-02 | — | — | US | disclosed |
| EP-2393501-A1 | METHOD AND MEANS FOR PRODUCING TISSUES AND TISSUES OBTAINED | Philippart, Pierre (BE) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089379-A1 | METHOD AND MEANS FOR PRODUCING TISSUES AND TISSUES OBTAINED | PHILIPPART PIERRE (BE) | 2010-08-12 | — | — | WO | disclosed |
| WO-2009076454-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122159-A1 | Pharmaceutical formulation | CYP51A1, CYP11B2, CYP11B1 | NR3C1 65/4885HIF1A 3961/4885CYP3A4 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.